1. Name and Address of Reporting Person
    Himawan Jeff
    (Last)  (First)  (Middle)
    C/O HORIZON PHARMA PLC
    CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
    DUBLIN  L2  4

2. Issuer Name and Ticker or Trading Symbol
    Horizon Therapeutics Public Ltd Co [ HZNP ]

3. Date of Earliest Transaction (Month/Day/Year)
    04/30/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
    X Director
    10% Owner
    Officer (give title below)
    Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 4)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary Shares</td>
<td>05/02/2020</td>
<td></td>
<td></td>
<td>M</td>
<td>15,390</td>
<td>A (1)</td>
<td>I</td>
</tr>
<tr>
<td>Ordinary Shares</td>
<td>05/02/2020</td>
<td></td>
<td></td>
<td>F</td>
<td>4,151</td>
<td>D</td>
<td>35.62</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 5)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Derivative Security Beneficially Owned (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Restricted Stock Units</td>
<td>(1)</td>
<td>04/30/2020</td>
<td></td>
<td>A</td>
<td>11,098</td>
<td>04/30/2021</td>
<td>04/30/2021</td>
<td>Ordinary shares</td>
<td>11,098</td>
<td>$0.00</td>
<td>11,098</td>
</tr>
<tr>
<td>Restricted Stock Units</td>
<td>(1)</td>
<td>05/02/2020</td>
<td></td>
<td>M</td>
<td>15,390</td>
<td>(2)</td>
<td>(2)</td>
<td>Ordinary shares</td>
<td>15,390</td>
<td>$0.00</td>
<td>0</td>
</tr>
</tbody>
</table>

Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
2. On May 2, 2019, the reporting person was granted 15,390 restricted stock units, vesting in full on the first anniversary of the grant date.

Remarks:

As Miles W. McHug Jr.
Attorney-in-Fact
05/04/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.